Skip to main content
. Author manuscript; available in PMC: 2020 Oct 3.
Published in final edited form as: Cell Rep. 2020 Sep 22;32(12):108169. doi: 10.1016/j.celrep.2020.108169

Figure 7. R-CV Treatment Has No Significant Effects on Aβ Accumulation but Protects against Neuron loss in 6- to 7-Month-Old 5xFAD+/− Mice.

Figure 7.

(A) Aβ deposition in 6- to 7-month-old 5xFAD+/− mice treated with DMSO or R-CV.

(B) Averaged Aβ plaque numbers in the hippocampal region of 6- to 7-month-old 5xFAD+/− mice treated with DMSO (12 mice, 36 slices) or R-CV (12 mice, 36 slices).

(C) Percentage of the hippocampal area showing positive Aβ staining.

(D) Immunoblot analysis of brain tissue homogenates from 6- to 7-month-old 5xFAD+/− mice treated with DMSO or R-CV.

(E and F) Normalized total Aβ levels (E) and normalized Aβ (1–42) levels (F) in 5xFAD+/− mice treated with DMSO (n = 10) or R-CV (n = 11).

(G) Images of Nissl staining of 6- to 7-month-old 5xFAD+/− mice treated with DMSO or R-CV.

(H) Numbers of pyramidal neurons in the subiculum region (red oval) of 6- to 7-month-old 5xFAD+/− mice treated with DMSO (12 mice, 36 slices) or R-CV (12 mice, 36 slices).

(I) Images of Nissl staining of 6- to 7-month-old 5xFAD+/− mice treated with DMSO or R-CV.

(J) Numbers of pyramidal neurons in the CA1 region of 6- to 7-month-old 5xFAD+/− mice treated with DMSO (12 mice, 36 slices) or R-CV (12 mice, 36 slices).

Scale bars, 2 mm in (A) and 200 μm in (G) and (I).

Data shown are the median and range (Mann-Whitney U test; **p < 0.01 compared with the DMSO group). See also Figure S7.

HHS Vulnerability Disclosure